key: cord-0947503-bg28wxub
authors: Hu, Suwen; Jiang, Songwei; Qi, Xiang; Bai, Renren; Ye, Xiang‐Yang; Xie, Tian
title: Races of small molecule clinical trials for the treatment of COVID‐19: An up‐to‐date comprehensive review
date: 2021-11-11
journal: Drug Dev Res
DOI: 10.1002/ddr.21895
sha: 5b159018755abf04712dfa0f8e74d5dea1f8b83f
doc_id: 947503
cord_uid: bg28wxub

The coronavirus disease‐19 (COVID‐19) pandemic has become a global threat since its first outbreak at the end of 2019. Several review articles have been published recently, focusing on the aspects of target biology, drug repurposing, and mechanisms of action (MOAs) for potential treatment. This review gathers all small molecules currently in active clinical trials, categorizes them into six sub‐classes, and summarizes their clinical progress. The aim is to provide the researchers from both pharmaceutical industries and academic institutes with the handful information and dataset to accelerate their research programs in searching effective small molecule therapy for treatment of COVID‐19.

Since its first large-scale outbreak in central China in December 2019, the severe acute respiratory syndrome coronavirus 2 (SARS- has caused the coronavirus disease-19 (COVID-19) pandemic globally (Sahin et al., 2020; Wang, Hu, et al., 2020) , and has led to severe damage to human lives and the economy of more than 200 countries worldwide. By the time this manuscript is submitted, 143,445,675 people have been infected by this virus, and the death toll mounts up to 3,051,736 globally (World Health Organization website, n.d.).

Besides SARS-CoV-2, six more coronaviruses have been characterized by now: human CoV229E (HCoV-229E, 1966) , human CoV OC43 (HCoV-OC43, 1967) , human CoV HKU1 (HCoV-HKU1, 2004) , human CoV NL63 (HCoV-NL63, 2004) , severe acute respiratory syndrome CoV (SARS-CoV, 2003) , and Middle East respiratory syndrome CoV (MERS-CoV, 2013) . Chronological analysis of the commence time and severity of these viruses suggests that the outbreak cycle of the coronaviruses is getting shorter and shorter, and the impact of the viruses is getting worse and worse. To treat current SARS-CoV-2 infection, and more importantly to prepare for unforeseeable new coronaviruses in the future, scientists from the globe respond quickly in attempt to identify suitable solutions such as small molecules for the potential therapy or vaccines for the prevention.

SARS-CoV-2 belongs to a class of coronaviruses featured with positive-sense, enveloped, single-stranded RNA (Zeidler & Karpinski, 2020) . The spike proteins (S proteins) on the viral envelope include two subunits, S1 and S2, which are the key surface proteins that participate in the interaction between the viruses and the host cells, and eventually promote the virus to enter the host cell (Walls et al., 2020) .SARS-CoV-2 uses angiotensin-converting enzyme 2 (ACE2) receptors to enter the lung cells (Figure 1a ). After the attachment of the virus to the host cells, the S protein of the virus interacts with protease enzymes from the host cells, enabling the virus fusing to the host cell membrane (Cascella et al., 2021) . This process relies on transmembrane serine protease (TMPRSS2) activating S proteins (Hoffmann et al., 2020; Valencia, 2020) . After the genomic RNA released into the cytoplasm and then translated to produce polyproteins, which is facilitated by virally encoded chymotrypsin-like protease (3CL pro ) or main protease (M pro ) (Cascella et al., 2021) .

Polyproteins cleavage affords non-structural proteins for the viral RNA replicase-transcriptase complex. Viral nucleocapsids are assembled with the structural proteins after the viral replication and transcription. Upon encasing viral RNA, these nucleocapsids form the new virions and are then released from the cells via exocytosis (Valencia, 2020) . Clinical studies indicate that several cytokines from severe patients' tissue undergo extensive changes, which play a crucial role in the COVID-19 pathogenesis (Liu, Zhang, Huang, Yang, et al., 2020; Mehta, McAuley, et al., 2020; Wan et al., 2020) . Hypercytokinemia (also known as "cytokine storm") may play as a pivotal role in life-threatening pathological processes ( Figure 1b) (Xu, Shi, Li, & Zhou, 2020; Xu, Shi, Wang, et al., 2020) . It has been proven that CD4 + T cells are rapidly activated to secret inflammatory cytokines upon the infection with SARS-CoV-2, which further lead to CD14 + CD16 + monocyte activation with high interleukin expression (such as IL-1, IL-6 etc. see Figure 1b ) (Zhou, Fu, et al., 2020) . Thus, blocking the IL-1 or the IL-6 receptors could potentially alleviate F I G U R E 1 (a) Schematic illustration of the replication cycle of SARS-CoV-2 and the biological targets for the potential treatment. (b) the inhibition of excessive inflammatory response. (c) SARS-CoV-2 infects type II alveolar epithelial cells (type II AEC) via the interaction between its S proteins and the ACE2 receptor by promoting internalization and degradation of ACE2 and pulmonary ACE/ACE2 imbalance. In turn, the degradation of angiotensin II (AT II) into angiotensin 1-7 (AT-1-7) is prevented (dotted arrows), reducing anti-inflammatory signaling through the mas receptor (MasR), and promoting pro-inflammatory AT II signaling through the angiotensin receptor type I (AT1R) in vascular endothelial cells. Complex interactions involving the renin-angiotensin system, oxidative state, endothelial interaction, and immune activation lead to alveola edema, lung inflammation, microvascular thrombosis, and acute respiratory distress syndrome. Potential targets have been identified as possible pharmacotherapies for the prevention, treatment, or management of COVID-19 immunopathology caused by SARS-CoV-2. The pulmonary reninangiotensin system (RAS) is composed by two pathways, whose balance is crucial for pulmonary homeostasis (Figure 1c ). Angiotensin II (Ang II), generated by endothelial ACE, acts on angiotensin II receptor type 1 (AT1) to promote pro-inflammatory effects and vasoconstriction, whereas epithelial ACE2 cleaves Ang II into Ang (1-7), which acts on the MAS1 (MAS proto-oncogene) oncogene to exert antiinflammatory and vasodilatory effects. The ACE-dependent Ang II formation is a vital pathophysiological mechanism in different forms of acute respiratory distress syndrome (ARDS) (South et al., 2020) .

SARS-CoV-2 interacts with ACE2, triggers ACE2 degradation and the ratio of ACE/ACE2 imbalance, further drives Ang II-mediated vascular inflammation and pulmonary injury which lead to severe COVID-19 symptoms (Figure 1c ) (South et al., 2020) .

Global scientific communities and pharmaceutical industries have been racing for success to cope with the COVID-19 pandemic in two major approaches: vaccines for the prevention (Buchholz et al., 2004; Cheng et al., 2020) and small molecule drugs for the potential treatment (Clinical trial ID: NCT04252885, n.d.; Cava et al., 2020; Kadam & Wilson, 2017; Lu, 2020; Pant et al., 2021; Sheahan, Sims, Leist, et al., 2020; Wu et al., 2020; Zhou, Hou, et al., 2020) . The vaccine approach might ultimately be the most effective solution to the current pandemic (Karpi nski et al., 2021) . However, the small molecule approach is also pivotally important and desperately needed. Such approach not only could treat the patients at high risk or in critical condition in the current pandemic but also could prepare for diseases caused by unforeseeable new coronaviruses in the future.

Since 2020, several review articles have been published regarding the advances of coronavirus treatment in different aspects. For example, Pillaiyar et al. (2020) reviewed the small molecule inhibitors for the potential treatment of coronavirus by focusing on the drug repurposing and drug discovery stage. Zhu et al. (2021 ), Zeng et al. (2020 used the deep learning approach to identify 41 old drugs potentially repurposable for treatment of COVID-19. Jean et al. (2020) reviewed the treatment reality and challenges for COVID-19. Zhang & Penninger et al. (2020) reviewed the ACE2 as a potential therapeutic target for COVID-19. Ghosh et al. (2020) (Yousefi et al., 2021) . In addition to above reviews, other approaches such as drug repurposing strategy (DRS) (Sahoo et al., 2021) , system biology (Jaiswal et al., 2020) , and computation practices (Ojha et al., 2021) were also reviewed recently.

Focusing on the small molecule approach, this article systematically summarizes those small molecules in current clinical trials for the potential treatment of COVID-19 in a comprehensive manner. By the time this review is submitted (April 22, 2021) (Tobinick, 2009) , is of particular interest in the response to the COVID-19 pandemic emergency and urgency. Historic data suggest that de novo drug development typically takes 10 to 17 years and costs 800 million USD (Tobinick, 2009 ). Therefore, de novo drugs approach for combating COVID-19 might not turn out to be effective and satisfactory in the current pandemic emergency. On the other hand, the drug repurposing approach has been proven to be practical and successful in several cases. This approach significantly shortens the development time and reduces the cost. Repurposing existing drugs to treat COVID-19 is biologically feasible as SARS-CoV-2 shares some similarities with other coronaviruses, such as SARS-CoV and MERS-CoV (Chen, Tian, et al., 2020) , and there are many successful precedents in repurposing antivirals for new virus targets (Mercorelli et al., 2018) .

Indeed, most of the drugs currently in clinical trials for COVID-19 are repurposed from approved antiviral drugs.

Data mining on more than four thousand clinical trials related to COVID-19 provided us with a pretty large dataset related to small molecules approach. To better discuss them, those small molecules were categorized into six classes based on the clinical features of COVID-19 and possible MOAs. The purpose of this review is to provide the researchers from both pharmaceutical industries and academic institutes with a comprehensive summary in this field so that to save their time in drug discovery research and to accelerate the finding of effective therapy for COVID-19.

To facilitate the interity of the review, we manually sorted out the drugs currently in clinical trials by querying the drug database from the FDA. Thus, for each identified small molecular drug, we searched for clinical trials on NIH Clinical Trials website using the name of drug plus "COVID-19" and screened thoroughly the results (2) inhibiting viral replication (29 agents, accounting for 23%);

(3) addressing cytokine storm syndrome (CSS) (51 agents, accounting for 40%); (4) modulating immune system (10 agents, accounting for 8%); (5) anticoagulant therapy (7 agents, accounting for 6%); and (6) 

Mounting studies suggest that SARS-CoV-2 invades into the membrane of the host cells mainly through the endocytosis after the S protein binding to ACE2 on the surface of the host cells (Yang & Shen, 2020) . Then the S protein with the altered configuration facilitates the viral envelope to fuse with the host cell membrane via the endosome pathway. At present, agents such as bromhexine, camostat, arbidol, linagliptin, chlorpromazine, etc. are being tested to block endocytosiswhile hydroxychloroquine and chloroquine are being investigated to block the viral genome released into the cytoplasm.

However, the data from clinical trials indicate that antimalarial drug hydroxychloroquine neither helps COVID-19 patients improve the recovery or reduce their symptoms nor prevents coronavirus infection in healthy people (Self et al., 2020) . Both the World Health Organization (WHO) and NIH have suspended the clinical trials related to chloroquine class of medicines. The ongoing clinical trials of potential drugs targeting to block viral entry into the host cells are summarized in Table 1 .

There are two mainly targets inhibiting virus replication: (1) the protease (3CL pro and PL pro ); and (2) the RNA-dependent RNA polymerase (RdRP). Anti-HIV agents (lopinavir or ritonavir) inhibit protease 3CL pro , thereby blocking the formation of non-structural proteins. In July 2020, the WHO announced the suspension of the lopinavir/ ritonavir combination clinical trial, citing little or no effect in reducing the death rate of hospitalized COVID-19 patients in the branch trial (News press from WHO website, 2021). PF-07321332 and PF-07304814 are potent and orally active SARS-CoV 3C-like protease (3CL pro ) inhibitors currently in multiple clinical trials including Phase F I G U R E 2 All of the small molecules in COVID-19 clinical trials as of April 22, 2021: Categorizing these trials depending upon the clinical features of COVID-19 and their probable MOAs. The hexagon contains small molecular compounds in different clinical trial stages: Phase I to phase IV from the inside to the outside III (Vandyck & Deval, 2021) . On the other hand, RdRP inhibitors such as remdesivir (Grein et al., 2020) , sofosbuvir, and galidesivir could block the replication of the viral genome and the formation of structural proteins. Discovered by Gilead Sciences, remdesivir is the first drug to receive emergency FDA approval as sympathy medication for COVID-19 patients and is currently under various forms of approval in several countries. Especifically, molnupiravir (aka EIDD-2801 and MK-4482) induced RNA mutagenesis by the viral RNAdependent RdRp. Molnupiravir showed an exciting experimental results in phase 2 clinical trials, and was one of the most promising small molecule anti-coronavirus drugs at present (Imran et al., 2021; Kabinger & Stiller, 2021; Malone & Campbell, 2021 (Fajgenbaum & June, 2020; Gao et al., 2021) . Abundant studies have revealed that majority of COVID-19 patients are often have higher levels of inflammatory mediators in blood. Those inflammatory mediators include cytokines and chemokines such as interleukin (IL)-1 IL-6, IL-7, IL-10, IL-21, TNF, and monocyte chemoattractant protein-1 (MCP1, also known as CCL2) etc. Gorbalenya et al., 2020; Hojyo et al., 2020; Tay et al., 2020) . Therefore, COVID-19 could be featured as a cytokine release syndrome (CRS) and the fatality could be caused by the high mortality cytokine storm.

In fact, the approach on addressing the CSS for the potential treat- to the potential delay in viral clearance. Hence, corticosteroids should be given to patient with certain symptoms such as severe acute respiratory distress syndrome or refractory septic shock (Mehta, Mazer-Amirshahi, et al., 2020) . Agents in clinical trials for potential inhibiting cytokine storm in COVID-19 are summarized in Table 3 .

Special cells (such as white blood cells B-and T-lymphocytes), organs (such as bone marrow, spleen, and thymus), and chemicals (antibodies) mainly compose the immune system (Sompayrac, 2019) . The wellworking immune system produces antibodies to kill pathogens and protects the body against viruses and diseases. The immune system in human body plays a fundamental role in maintaining health (Chowdhury et al., 2020) . After invasion into the human body, SARS-CoV-2 will encounters a robust innate immune response when it moves to the respiratory tract (Rokni et al., 2020; Tang et al., 2005 ).

The immune system plays a critical role in the body's defenses against (Kutlu & Metin, 2020; Papic et al., 2020) suppress the virus infection through modulation of the immune system (Table 4 ).

SARS-CoV-2 can invade cells lining blood vessels and cause a series of consequences related to cardiovascular diseases and thrombosis.

More specifically, the virus invasion could induce endothelial dysfunction which further leads to pulmonary thrombi (Carfora et al., 2021; Poissy et al., 2020) . Applying anticoagulant therapy in COVID 19 patients has scientific support and is in line with the COVID-19 global pandemic emergency. Agents such as rivaroxaban and apixaban are in ongoing clinical trials to combat COVID-19 associated hypercoagulation ( Figure 2 and Table 5 ). The efficacy and effectiveness of using anticoagulant therapy for COVID-19 await clinical data. 

The primary goal of Phase I study is to assess the safety, the tolerability, the pharmacokinetic parameters, and the pharmacodynamics effects of a drug candidate in healthy volunteers. At the end of this phase, the optimum dose and formulation will be determined. The 

Phase III clinical trials are the studies in the efficacy confirmatory stage. Its goal is to further verify the therapeutic effectiveness and the safety of a drug candidate on patients with specific indications, and to assess the overall risk-benefit relationships. The results from this stage trial will ultimately provide substantial ground for the new drug registration applications. In this stage of the trial, a larger array of trials and more patients will be required and assessed than those tirals in phase II 

Phase IV clinical trial is conducted by the applicant after the new drug has already been approved by FDA. The main objective in this phase is to assess the long-term benefits and risks of using the drug in general population groups or in special population groups. In category, there are 34 agents in approximately 386 trials (Figure 4 ). Among them, 10 agents aim at blocking virus-cell membrane fusion and entry, 7 small molecules inhibit viral replication, 11 small molecules address CSS, 1 small molecule modulates immune system. In addition, there are currently 2 agents used as anticoagulant therapy and 3 agents identified as antioxidant supplements.

Of those drugs blocking virus-cell membrane fusion and entry, three agents are TMPRSS2 inhibitors (bromhexine, camostat, and spironolactone), three agents (valsartan, arbidol and canrenoate potassium) interact with ACE2, one agent (azithromycin) interfers with S protein/CD147 interaction, one agent (tetrandrine) inhibits voltage- 

At present, several COVID-19 vaccines have been approved for clinical use in many countries worldwide. The vaccine approach aims at the preventive management, which will increase antibody level against the virus and reduce the probability for viral infection in a certain extend. However, the vaccine approach is not suitable for those peo- 

Potential repurposed SARS-CoV-2 (COVID-19) infection drugs

Pakistan randomized and observational trial to evaluate coronavirus treatment (PROTECT) of Hydroxychloroquine, Oseltamivir and azithromycin to treat newly diagnosed patients with COVID-19 infection who have no comorbidities like diabetes mellitus: A structured summary of a study protocol for a randomized controlled trial

Potential therapeutic roles for direct factor Xa inhibitors in coronavirus infections

Tamoxifen from chemotherapy to antiviral drug: Possible activity against COVID19

Ramipril in high-risk patients with COVID-19

COVID-19: The potential role of copper and N-acetylcysteine (NAC) in a combination of candidate antiviral treatments against SARS-CoV-2

Pentoxifylline and complicated COVID-19: A pathophysiologically based treatment proposal

Preventive efficacy of Tenofovir/Emtricitabine against severe acute respiratory syndrome coronavirus 2 among preexposure prophylaxis users

Melatonin potentials against viral infections including COVID-19: Current evidence and new findings

Vitamin C for COVID-19: A living systematic review

COVID-19 infection in a patient with multiple sclerosis treated with fingolimod

Is acetylsalicylic acid a safe and potentially useful choice for adult patients with COVID-19 ?

Discovery of a Novel Inhibitor of Coronavirus 3CL Protease for the Potential Treatment of COVID-19

Montelukast's ability to fight COVID-19 infection

Contributions of the structural proteins of severe acute respiratory syndrome coronavirus to protective immunity

Spironolactone may provide protection from SARS-CoV-2: Targeting androgens, angiotensin converting enzyme 2 (ACE2), and renin-angiotensin-aldosterone system (RAAS)

Baricitinib therapy in COVID-19: A pilot study on safety and clinical impact

A trial of Lopinavir-ritonavir in adults hospitalized with severe Covid-19

Anticoagulant treatment in COVID-19: A narrative review

Vitamin C and immune function

Features, evaluation, and treatment of coronavirus (COVID-19)

Sex hormones and hormone therapy during COVID-19 pandemic: Implications for patients with cancer

In Silico discovery of candidate drugs against Covid-19

Aminoglycosides can be a better choice over macrolides in COVID-19 regimen: Plausible mechanism for repurposing strategy. Medical Hypotheses

Lactoferrin as potential preventative and adjunct treatment for COVID-19

Overview of lethal human coronaviruses

Clinical and immunological features of severe and moderate coronavirus disease 2019

Inhibition of severe acute respiratory syndrome coronavirus 2 main protease by tafenoquine in vitro

Organ-protective effect of angiotensin-converting enzyme 2 and its effect on the prognosis of COVID-19

Nucleotide analogues as inhibitors of SARS-CoV-2 polymerase

BTK inhibitors in cancer patients with COVID-19: "the winner will be the one who controls that chaos" (Napoleon Bonaparte)

Naltrexone a potential therapeutic candidate for COVID-19

Immune response in COVID-19: A review

Role of lopinavir/ritonavir in the treatment of SARS: Initial virological and clinical findings

Clinical trial ID: NCT04255017

Clinical trial ID: NCT04414618

Quercetin and vitamin C: An experimental, synergistic therapy for the prevention and treatment of SARS-CoV-2 related disease (COVID-19)

Favipiravir, an antiviral for COVID-19?

Time to consider histologic pattern of lung injury to treat critically ill patients with COVID-19 infection

Can dapagliflozin have a protective effect against COVID-19 infection? A hypothesis. Diabetes and Metabolic Syndrome

Commentary: Could iron chelators prove to be useful as an adjunct to COVID-19 treatment regimens? Metabolism

Clinical pharmacology perspectives on the antiviral activity of azithromycin and use in COVID-19

Docking adenosine receptor ligands to SARS-CoV2 mRNA cap 2'-O-Methyltransferase

Aspects of inflammatory bowel disease during the COVID-19 pandemic and general considerations

Colchicine as a potent antiinflammatory treatment in COVID-19: Can we teach an old dog new tricks?

Late pulmonary embolism after COVID-19 pneumonia despite adequate rivaroxaban treatment

Mechanistic aspects and therapeutic potential of Quercetin against COVID-19-associated acute kidney injury

Tafenoquine inhibits replication of SARS-Cov-2 at pharmacologically relevant concentrations in vitro

Use of enoxaparin to counteract COVID-19 infection and reduce thromboembolic venous complications: A review of the current evidence

Advance of promising targets and agents against COVID-19 in China

Intravenous methylprednisolone pulse as a treatment for hospitalised severe COVID-19 patients: Results from a randomised controlled clinical trial. The European Respiratory

Ribavirin, Remdesivir, Sofosbuvir, Galidesivir, and Tenofovir against SARS-CoV-2 RNA dependent RNA polymerase (RdRp): A molecular docking study

Histamine receptors and COVID-19

Cytokine Storm

Identification of FDA Approved Drugs Targeting COVID-19 Virus by Structure-Based Drug Repositioning

Baricitinib for COVID-19: A suitable treatment?

Exploring sodium glucose co-Transporter-2 (SGLT2) inhibitors for organ protection in COVID-19

As a potential treatment of COVID-19: Montelukast. Medical Hypotheses, 142, 109828

Doxycycline or minocycline may be a viable treatment option against SARS-CoV-2. Medical Hypotheses, 144, 110054

Severe acute lung injury related to COVID-19 infection: A review and the possible role for Escin

Cytokine storm syndrome in coronavirus disease 2019: A narrative review

Atorvastatin and aspirin as adjuvant therapy in patients with SARS-CoV-2 infection: A structured summary of a study protocol for a randomised controlled trial

Drug development and medicinal chemistry efforts toward SARS-coronavirus and Covid-19 therapeutics

The potential of JAK/STAT pathway inhibition by ruxolitinib in the treatment of COVID-19

Potential usefulness of pentoxifylline, a nonspecific phosphodiesterase inhibitor with anti-inflammatory, antithrombotic, antioxidant, and anti-fibrogenic properties, in the treatment of SARS-CoV-2

AT-527, a double Prodrug of a Guanosine nucleotide analog, is a potent inhibitor of SARS-CoV-2 in vitro and a promising Oral antiviral for treatment of COVID-19

The species severe acute respiratory syndrome-related coronavirus: Classifying 2019-nCoV and naming it SARS-CoV-2

Compassionate use of Remdesivir for patients with severe Covid-19

Angiotensin receptor blockers as tentative SARS-CoV-2 therapeutics

Possible use of the mucolytic drug, bromhexine hydrochloride, as a prophylactic agent against SARS-CoV-2 infection based on its action on the Transmembrane serine protease 2

Could patients taking isotretinoin therapy be immune against SARS-CoV-2?

Ebselen, a new candidate therapeutic against SARS-CoV-2

Ivermectin: A systematic review from antiviral effects to COVID-19 complementary regimen

Pharmacological hypothesis: TPC2 antagonist tetrandrine as a potential therapeutic agent for COVID-19

Consensus statement. Corticosteroid therapy in ENT in the context of the COVID-19 pandemic

SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor

How COVID-19 induces cytokine storm with high mortality

Dexamethasone in hospitalized patients with Covid-19

The in vitro antiviral activity of lactoferrin against common human coronaviruses and SARS-CoV-2 is mediated by targeting the heparan sulfate co-receptor

Pharmacological therapeutics targeting RNA-dependent RNA polymerase, proteinase and spike protein: From mechanistic studies to clinical trials for COVID-19

Clevudine for the treatment of chronic hepatitis B virus infection

The clinical effects of vitamin C supplementation in elderly hospitalised patients with acute respiratory infections

Immunic Therapeutics website

Discovery, development, and patent trends on molnupiravir: a prospective oral treatment for COVID-19

Systems biology approaches for therapeutics development against COVID-19

Clevudine for chronic hepatitis B: Antiviral response, predictors of response, and development of myopathy

Treatment options for COVID-19: The reality and challenges

Mechanism of molnupiravir-induced SARS-CoV-2 mutagenesis

Structural basis of influenza virus fusion inhibition by the antiviral drug Arbidol

The 2020 race towards SARS-CoV-2 specific vaccines

Nitazoxanide/azithromycin combination for COVID-19: A suggested new protocol for early management

Thalidomide-revisited: Are COVID-19 patients going to be the latest victims of yet another theoretical drug-repurposing?

Novel coronavirus treatment with ribavirin: Groundwork for an evaluation concerning COVID-19

Molecular pharmacology of ciclesonide against SARS-CoV-2

Blocking inflammation on the way: Rationale for CXCR2 antagonists for the treatment of COVID-19

Preventing cytokine storm syndrome in COVID-19 using α-1 adrenergic receptor antagonists

COVID-19-the potential beneficial therapeutic effects of spironolactone during SARS-CoV-2

Battling COVID-19: Using old weapons for a new enemy

Compassionate use of opaganib for patients with severe COVID-19

A case of exacerbation of psoriasis after oseltamivir and hydroxychloroquine in a patient with COVID-19: Will cases of psoriasis increase after COVID-19 pandemic?

Application of atorvastatin calcium in preparation of drug for treating new coronary pneumonia

Therapeutic options for the 2019 novel coronavirus (2019-nCoV)

Blocking mineralocorticoid receptor with spironolactone may have a wide range of therapeutic actions in severe COVID-19 disease

Successful use of methylprednisolone for treating severe COVID-19

Therapeutic effects of dipyridamole on COVID-19 patients with coagulation dysfunction

Potential therapeutic effects of dipyridamole in the severely ill patients with COVID-19

Elevated plasma levels of selective cytokines in COVID-19 patients reflect viral load and lung injury

Drug treatment options for the 2019-new coronavirus (2019-nCoV)

Preventing mortality in COVID-19 patients: Which cytokine to target in a raging storm?

The DHODH inhibitor PTC299 arrests SARS-CoV-2 replication and suppresses induction of inflammatory cytokines

Ebselen, Disulfiram, Carmofur, PX-12, Tideglusib, and Shikonin are nonspecific promiscuous SARS-CoV-2 Main protease inhibitors

Validation and invalidation of SARS-CoV-2 main protease inhibitors using the Flip-GFP and Protease-Glo luciferase assays

Dipyridamole, chloroquine, montelukast sodium, candesartan, oxytetracycline, and atazanavir are not SARS-CoV-2 main protease inhibitors

Defibrotide in the COVID-19 coagulopathy: What is the timing?

Repurposing the mucolytic cough suppressant and TMPRSS2 protease inhibitor bromhexine for the prevention and management of SARS-CoV-2 infection

Drug repurposing of nitazoxanide: Can it be an effective therapy for COVID-19?

Molnupiravir: Coding for catastrophe

Vitamin D supplementation to prevent acute respiratory tract infections: Systematic review and meta-analysis of individual participant data

A Combination of Ivermectin and Doxycycline Possibly Blocks the Viral Entry and Modulate the Innate Immune Response in COVID-19 Patients

Estradiol, progesterone, immunomodulation, and COVID-19 outcomes

Optimisation of vitamin D status for enhanced Immuno-protection against Covid-19

Proxalutamide reduces the rate of hospitalization for COVID-19 male outpatients: A randomized doubleblinded placebo-controlled trial

Candidate drugs against SARS-CoV-2 and COVID-19

Aprepitant as a combinant with dexamethasone reduces the inflammation via Neurokinin 1 receptor antagonism in severe to critical Covid-19 patients and potentiates respiratory recovery: A novel therapeutic approach. medRxiv

Pharmacotherapy in COVID-19; a narrative review for emergency providers

COVID-19: Consider cytokine storm syndromes and immunosuppression

Drug repurposing for viral infectious diseases: How far are we?

COVID-19 and renin angiotensin blockers: Current evidence and recommendations. Circulation

Drug repurposing of approved drugs Elbasvir, Ledipasvir, Paritaprevir, Velpatasvir, Antrafenine and Ergotamine for Combating COVID19

Successful recovery of COVID-19 pneumonia in a patient from Colombia after receiving chloroquine and clarithromycin

COVID-19 associated complications and potential therapeutic targets

Can colchicine as an old antiinflammatory agent be effective in COVID-19?

Ruxolitinib for the treatment of SARS-CoV-2 induced acute respiratory distress syndrome (ARDS)

News press from WHO website WHO discontinues hydroxychloroquine and lopinavir/ritonavir treatment arms for COVID-19

Consideration of Tranexamic acid administration to COVID-19 patients

Therapeutics for COVID-19: from computation to practices-where we are, where we are heading to

The chemokine receptor antagonist cenicriviroc inhibits the replication of SARS-CoV-2 in vitro

Targeting T-cell senescence and cytokine storm with rapamycin to prevent severe progression in COVID-19

Pulmonary delivery of Fenretinide: A possible adjuvant treatment in COVID-19

Peptide-like and small-molecule inhibitors against Covid-19

Trends of late presentation to Care in Patients with chronic hepatitis C during a 10-year period in Croatia

Povidoneiodine gargle as a prophylactic intervention to interrupt the transmission of SARS-CoV-2

Fingolimod for multiple sclerosis

Review of safety and minimum pricing of nitazoxanide for potential treatment of COVID-19

Low-dose hydrocortisone in patients with COVID-19 and severe hypoxia (COVID STEROID) trial-protocol and statistical analysis plan

Recent discovery and development of inhibitors targeting coronaviruses

Plausible mechanisms of Niclosamide as an antiviral agent against COVID-19. Medical Hypotheses

Repurposing chlorpromazine to treat COVID-19: The reCoVery study

N-Acetylcysteine: A potential therapeutic agent for SARS-CoV-2

Pulmonary embolism in patients with COVID-19: Awareness of an increased prevalence

Molecular docking and dynamic simulations of Cefixime, Etoposide and Nebrodenside a against the pathogenic proteins of SARS-CoV-2

Maraviroc inhibits SARS-CoV-2 multiplication and s-protein mediated cell fusion in cell culture

Immune responses and pathogenesis of SARS-CoV-2 during an outbreak in Iran: Comparison with SARS and MERS

Inhibition of Bruton tyrosine kinase in patients with severe COVID-19

Cyclosporine therapy during the COVID-19 pandemic

In silico potential of approved antimalarial drugs for repurposing against COVID-19

Anti-inflammatory potential of Quercetin in COVID-19 treatment

2019 novel coronavirus (COVID-19) outbreak: A review of the current literature

Drug repurposing strategy (DRS): Emerging approach to identify potential therapeutics for treatment of novel coronavirus infection

Amiodarone in the COVID-19 era: Treatment for symptomatic patients only, or drug to prevent infection?

Pharmacologic treatments for coronavirus disease 2019 (COVID-19): A review

Sofosbuvir as repurposed antiviral drug against COVID-19: Why were we convinced to evaluate the drug in a registered/approved clinical trial? Archives of Medical Research

Effect of Hydroxychloroquine on clinical status at 14 days in hospitalized patients with COVID-19: A randomized clinical trial

Glecaprevir and Maraviroc are high-affinity inhibitors of SARS-CoV-2 main protease: Possible implication in COVID-19 therapy

Ivermectin, a new candidate therapeutic against SARS-CoV-2/COVID-19

Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV

An orally bioavailable broadspectrum antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in mice

Interactions between Remdesivir, ribavirin, Favipiravir, Galidesivir, Hydroxychloroquine and Chloroquine with fragment molecular of the COVID-19 Main protease with inhibitor N3 complex (PDB ID:6LU7) using molecular docking

Coronavirus S protein-induced fusion is blocked prior to hemifusion by Abl kinase inhibitors

Dipeptidyl peptidase-4 (DPP4) inhibition in COVID-19

How the immune system works

Controversies of renin-angiotensin system inhibition during the COVID-19 pandemic

Ketamine use in the COVID-19 era: Be cautious!

Statin use is associated with lower disease severity in COVID-19 infection

Early enhanced expression of interferon-inducible protein-10 (CXCL-10) and other chemokines predicts adverse outcome in severe acute respiratory syndrome

The trinity of COVID-19: Immunity, inflammation and intervention

Role of cyclophilin a during coronavirus replication and the antiviral activities of its inhibitors

The value of drug repositioning in the current pharmaceutical market

Ribavirin therapy for severe COVID-19: A retrospective cohort study

Merimepodib, an IMPDH inhibitor, suppresses replication of Zika virus and other emerging viral pathogens

The BTK inhibitor ibrutinib may protect against pulmonary injury in COVID-19-infected patients

Exportin 1 inhibition as antiviral therapy

CD147 as a target for COVID-19 treatment: Suggested effects of azithromycin and stem cell engagement

Can Levamisole be used in the treatment of COVID-19 patients presenting with diarrhea

Brief review on COVID-19: The 2020 pandemic caused by SARS-CoV-2

Considerations for the discovery and development of 3-chymotrypsin-like cysteine protease inhibitors targeting SARS-CoV-2 infection. Current Opinion in Virology

Beta-adrenergic blockers as a potential treatment for COVID-19 patients

Sacubitril, valsartan and SARS-CoV-2

Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein

Characteristics of lymphocyte subsets and cytokines in peripheral blood of 123 hospitalized patients with 2019 novel coronavirus pneumonia (NCP)

Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan

Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro

Disulfiram-mediated inhibition of NF-kappaB activity enhances cytotoxicity of 5-fluorouracil in human colorectal cancer cell lines

Does vitamin D deficiency increase the severity of COVID-19?

The role of oseltamivir in the treatment and prevention of influenza in children

World Health Organization website. Coronavirus (COVID-19) data

An update on current therapeutic drugs treating COVID-19

Broad Spectrum antiviral agent Niclosamide and its therapeutic potential

Pathological findings of COVID-19 associated with acute respiratory distress syndrome

Advantages of the parent nucleoside GS-441524 over Remdesivir for Covid-19 treatment

Targeting the Endocytic pathway and autophagy process as a novel therapeutic strategy in COVID-19

The pathogenesis and treatment of the "cytokine storm" in COVID-19

Repurposing existing drugs for the treatment of COVID-19/SARS-CoV-2 infection: A review describing drug mechanisms of action

SARS-CoV, MERS-CoV, SARS-CoV-2 comparison of three emerging coronaviruses

Repurpose open data to discover therapeutics for COVID-19 using deep learning

Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: Molecular mechanisms and potential therapeutic target

Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved α-ketoamide inhibitors

Aberrant pathogenic GM-CSF+ T cells and inflammatory CD14+ CD16+ monocytes in severe pulmonary syndrome patients of a new coronavirus

Network-based drug repurposing for novel coronavirus 2019-nCoV/SARS-CoV-2

Recent insights for the emerging COVID-19: Drug discovery, therapeutic options and vaccine development

Races of small molecule clinical trials for the treatment of COVID-19: An up-to-date comprehensive review

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Data sharing is not applicable to this article as no new data were created or analyzed in this study.

https://orcid.org/0000-0002-3991-645XSongwei Jiang https://orcid.org/0000-0003-2698-7125Xiang Qi https://orcid.org/0000-0002-6408-2696Renren Bai https://orcid.org/0000-0002-3511-5794Xiang-Yang Ye https://orcid.org/0000-0003-3739-0930Tian Xie https://orcid.org/0000-0001-7066-1443